COMPANY PROFILE

Vect-Horus

Explore full profile

Designing and developing peptide-based vectors that facilitate the delivery of drugs or imaging agents into organs

Marseille, FranceFounded 2005Biotech & Life Sciences

Valuation $25–50M Last recorded · 2020

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Vect-Horus

Vect-Horus is a biotechnology company focused on enhancing the delivery of therapeutic and imaging agents across biological barriers using its proprietary targeting technology. The company serves pharmaceutical and biotechnology firms by providing solutions that improve the efficacy and precision of drug delivery systems. Operating in the healthcare and life sciences market, Vect-Horus employs a business model that involves partnerships, licensing agreements, and collaborative research projects to generate revenue. By leveraging its innovative technology, Vect-Horus aims to address unmet medical needs and improve patient outcomes.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2005
Headquarters: Marseille, France
Employees: 56
Open positions: None listed
Dealroom signal: 79.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, observatoire industrial tech, DT and LS, observatoire healthtech, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES D✓Equity / VC	Dec 2020	$5.8M	$37M	Undisclosed	—
SERIES D✓Equity / VC	Sep 2020	$7.4M	$29M	Undisclosed	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Revenue	Growth	EBITDA	Margin	Profit	Margin
2026
2025
2024
2023
2022
2021
2020		—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Vect-Horus website traffic

Latest recorded traffic for Vect-Horus is 740 monthly website visits, up 25.4% over the last three months. Vect-Horus's team grew 9.8% over the past year.

Latest monthly visits740 3-month web change+25.4% 1-year team growth+9.8%

Monthly website visitsNov 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LTLys TherapeuticsInnovative biotherapies targeting neurological diseases with a focus on stroke and multiple sclerosis	Caen, France	Operational	15	$13M	$13M
TPTHX PharmaPharmaceuticals for rare neurological diseases and disorders.	Lyon, France	Operational
MEMedDayTherapeutics for the treatment of neuro-metabolic diseases	Paris, France	Closed
GBGenSight BiologicsDevelops innovative therapies for mitochondrial and neurodegenerative diseases	Paris, France	Operational
IPInBrain PharmaInnovative solutions against neurodegenerative diseases	Loos, France	Operational
ALAlzprotectBiopharmaceutical company which develop new bioactive molecules for the treatment of neurodegenerative diseases	Loos, France	Operational
ABActicor BiotechSafe and effective treatment of stroke	Paris, France	Operational
BTBrink TherapeuticsUnlocking in vivo cell therapy with the next generation of gene editing technology	Saint-Mandé, France	Operational